The RA-MAP Consortium: a working model for academia–industry collaboration

Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.

[1]  C. Lewis,et al.  EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis , 2012, Annals of the rheumatic diseases.

[2]  M. Morrison.  “A good collaboration is based on unique contributions from each side”: assessing the dynamics of collaboration in stem cell science , 2017, Life Sciences, Society and Policy.

[3]  S. Harada,et al.  Immunogenomics: using genomics to personalize cancer immunotherapy , 2017, Virchows Archiv.

[4]  W. Rogowski,et al.  What is personalized medicine: sharpening a vague term based on a systematic literature review , 2013, BMC Medical Ethics.

[5]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[6]  V A McKusick,et al.  Genomics and medicine. Dissecting human disease in the postgenomic era. , 2001, Science.

[7]  J. Vera,et al.  Systems Medicine for Lung Diseases: Phenotypes and Precision Medicine in Cancer, Infection, and Allergy , 2015, Methods in molecular biology.

[8]  N. Cohen,et al.  Open innovation networks between academia and industry: an imperative for breakthrough therapies , 2009, Nature Medicine.

[9]  R. Weinshilboum,et al.  Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine , 2016, Nature Reviews Drug Discovery.

[10]  H. Borghaei,et al.  Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose? , 2017, Current Treatment Options in Oncology.

[11]  R. Kurzrock,et al.  Next generation predictive biomarkers for immune checkpoint inhibition , 2016, Cancer and Metastasis Reviews.

[12]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .

[13]  Jianxin Shi,et al.  Developing and evaluating polygenic risk prediction models for stratified disease prevention , 2016, Nature Reviews Genetics.

[14]  Mona Singh,et al.  Computational solutions for omics data , 2013, Nature Reviews Genetics.

[15]  D. Botstein,et al.  Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease , 2003, Nature Genetics.

[16]  John D. Isaacs,et al.  Cytokines in rheumatoid arthritis — shaping the immunological landscape , 2016, Nature Reviews Rheumatology.

[17]  M. Lieber.  Mechanisms of human lymphoid chromosomal translocations , 2016, Nature Reviews Cancer.

[18]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[19]  A. Nussenzweig,et al.  End-joining, translocations and cancer , 2013, Nature Reviews Cancer.

[20]  Adriano Barbosa-Silva,et al.  SmartR: an open-source platform for interactive visual analytics for translational research data , 2017, Bioinform..

[21]  Rudi Balling,et al.  Revolutionizing medicine in the 21st century through systems approaches. , 2012, Biotechnology journal.

[22]  Chris Gennings,et al.  Big and disparate data: considerations for pediatric consortia , 2017, Current opinion in pediatrics.

[23]  Andrew Jones,et al.  Drug discovery alliances , 2005, Nature Reviews Drug Discovery.

[24]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[25]  Leena Peltonen,et al.  Dissecting Human Disease in the Postgenomic Era , 2001, Science.

[26]  Matthias Gottwald,et al.  Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data , 2016, Frontiers in pharmacology.

[27]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[28]  O. Olopade,et al.  Effect of BRCA germline mutations on breast cancer prognosis , 2016, Medicine.

[29]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[30]  Lee Harland,et al.  Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery , 2009, Nature Reviews Drug Discovery.

[31]  M. Daly,et al.  Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.